Side-by-side · Research reference

TirzepatidevsVIP

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AFDA-ApprovedFlagship14/45 cited

BPhase 3HUMAN-REVIEWED9/42 cited

Tirzepatide

GIP+GLP-1 Dual Agonist · FDA-Approved

2.5–15 mgWeekly doseZEPBOUND (tirzepatide) injecti 2023

20.9%Body-weight ↓Jastreboff 2022

~5 daysHalf-lifeZEPBOUND (tirzepatide) injecti 2023

SQ · Abdomen / thigh / arm · Once weekly

VIP

Neuropeptide · VPAC1/VPAC2 Agonist · Emergency Use Authorization (COVID-19 ARDS)

IntravenousPrimary routeBrown 2023

ARDSLead indicationUdupa 2025

Phase 3Development stage

IV infusion · Inhaled (investigational)Brown 2023 Boesing 2022

01Mechanism of Action

Parameter

Tirzepatide

VIP

Primary target

GIP receptor (GIPR) + GLP-1 receptor (GLP-1R)Frias 2018

VPAC1 and VPAC2 G-protein-coupled receptorsUdupa 2025

Pathway

Dual GIPR/GLP-1R agonism → ↑insulin (glucose-dependent), ↓glucagon, ↓gastric emptying, ↓appetite, ↑energy expenditure (via GIP component)Jastreboff 2022 Frias 2018

VIP → VPAC1/VPAC2 activation → cAMP elevation → Pulmonary vasodilation + epithelial protection

Downstream effect

Profound glycemic improvement and weight reduction; cardiometabolic benefitsJastreboff 2022

Anti-inflammatory cytokine modulation, alveolar-capillary membrane stabilization, pulmonary smooth muscle relaxation, reduced neutrophil infiltration

Feedback intact?

Glucose-dependent insulin release preserves physiological feedback

Yes — exogenous VIP acts as physiological agonist

Origin

39-AA peptide with C-20 fatty-acid acylation. Single molecule with balanced GIP + GLP-1 affinityFrias 2018

Endogenous 28-amino-acid neuropeptide; synthetic analogue (aviptadil) identical to natural VIP

Antibody development

—

02Dosage Protocols

Parameter

Tirzepatide

VIP

Standard dose (T2D)

5–15 mg / weekZEPBOUND (tirzepatide) injecti 2023

—

Standard dose (weight)

5, 10, or 15 mg / week (titrated)ZEPBOUND (tirzepatide) injecti 2023 Jastreboff 2022

—

Titration schedule

2.5 mg → +2.5 mg every 4 weeks → 15 mg max

Slower titration mitigates GI side effects.

—

Evidence basis

FDA-approved · Phase 3 RCTs (SURMOUNT, SURPASS)Jastreboff 2022 ZEPBOUND (tirzepatide) injecti 2023

Phase 3 RCT (TESICO)Brown 2023

816-patient randomized controlled trial in COVID-19 ARDS.

Duration

Indefinite for chronic indication

—

Reconstitution

Pre-filled commercial pen. Research vial: bacteriostatic water per label.

Lyophilized powder reconstituted with sterile diluent per protocol

Timing

Once weekly, any time of day

—

Half-life

~5 days (116 h)ZEPBOUND (tirzepatide) injecti 2023

~2 minutes (plasma)

Rapid clearance necessitates continuous infusion.

Intravenous (ARDS protocol)

—

60–90 mcg/kg/day via continuous infusion

TESICO trial protocol for COVID-19 ARDS.

Infusion duration

—

12-hour continuous IV infusion dailyBrown 2023

Inhaled (investigational)

—

Variable dosing under clinical trial protocolsBoesing 2022

Delivered via nebulizer for direct pulmonary deposition.

Treatment duration

—

3–14 days (acute ARDS)

04Side Effects & Safety

Parameter

Tirzepatide

VIP

GI symptoms

Nausea, vomiting, diarrhea (common, dose-dependent)Jastreboff 2022

Nausea, diarrhea (VIP is endogenous GI peptide)

Injection site reaction

Mild erythema, pruritus

—

Pancreatitis risk

Rare; discontinue if suspectedZEPBOUND (tirzepatide) injecti 2023

—

Thyroid C-cell tumours

Boxed warning — contraindicated in MEN2 / MTC historyZEPBOUND (tirzepatide) injecti 2023

—

Hypoglycemia

Low as monotherapy; risk with sulfonylureas / insulin

—

Gallbladder events

Increased cholelithiasis

—

Pregnancy / OB

Contraindicated

—

Diabetic retinopathy

Rapid glycemic improvement may transiently worsen

—

Hypotension

—

Transient vasodilation-related blood pressure drop

Tachycardia

—

Reflex tachycardia secondary to vasodilation

Infusion site reactions

—

Erythema, phlebitis (IV administration)

Overall tolerability

—

Well-tolerated in Phase 3 trials; adverse event profile comparable to placebo

Absolute Contraindications

Tirzepatide

·MTC personal or family history; MEN2
·Pregnancy / breastfeeding
·Hypersensitivity to tirzepatide

VIP

·Known hypersensitivity to aviptadil or formulation components

Relative Contraindications

Tirzepatide

·Severe gastroparesis
·History of pancreatitis
·Diabetic retinopathy

VIP

·Severe hypotension or shock states (monitor blood pressure)
·Pregnancy — insufficient safety data

05Administration Protocol

Parameter

Tirzepatide

VIP

1. Reconstitution / device

Commercial: pre-filled pen / vial. Research lyophilised: bacteriostatic water per label.

Reconstitute lyophilized aviptadil powder with sterile diluent per manufacturer protocol. Inspect solution for particulates — should be clear and colorless.

2. Injection site

SQ — abdomen, thigh, or upper arm. Rotate weekly.

Administer as continuous 12-hour intravenous infusion via central or peripheral line. Use infusion pump for precise dosing (60–90 mcg/kg/day divided over infusion duration).

3. Timing

Once weekly, same day. Day change allowed if ≥3 days separate doses.

Monitor blood pressure, heart rate, and oxygenation continuously during first infusion. Assess for hypotension and adjust infusion rate if needed.

4. Storage

Refrigerate 2–8 °C unopened. Room temp ≤30 °C up to 21 days after first use.

Deliver via jet or mesh nebulizer per clinical trial protocol. Patient seated upright, normal tidal breathing for 10–15 minutes.

5. Needle

Pen-supplied. Research vial: 27–31G insulin syringe.

Store lyophilized powder at 2–8 °C, light-protected. Reconstituted solution: use immediately or within 24 hours if refrigerated.